Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of lenvatinib + pembrolizumab versus physician's choice chemotherapy in advanced endometrial cancer
MOH_2018-05-21_002382Phase 3Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lenvatinib, pembrolizumab, doxorubicin and paclitaxel in endometrial cancer (EC) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Efficacy versus chemotherapy and Safety and tolerability. Started Apr 2018; status: active, not recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on MOH_2018-05-21_002382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-21_002382.